Cell based cancer vaccines
DCprime has both the infrastructure and capabilities to bring cancer immunotherapeutics to clinic. Initially exploiting the proprietary DCOne® platform, DCprime is developing cell based vaccines against different types of cancer.
Immuno-oncology beyond T cells
Since successful vaccination requires an immune system capable of mounting an effective response to the vaccine, DCprime continues to invest in research into furthering understanding of the condition of the immune system during or after treatment of cancer.
- DCprime and Radboudumc to collaborate 14 March, 2019 Leiden, The Netherlands and Nijmegen, The Netherlands, March 2019– DCprime and Radboudumc announce that they will collaborate as part of a public-private consortium supported by The Dutch Top Sector Life Sciences and Health, represented by Stichting Life Sciences Health – TKI, also acting under its trade name Health~Holland, under the project title “Dendritic Cell Targeting ... Read more
- Dr Ada Kruisbeek resigns as CSO, assumes role as Chair of the Scientific Advisory Board 22 January, 2019 Leiden, The Netherlands, January 2019 – DCprime announces that Dr Ada Kruisbeek, founder, CSO and former CEO of the company, has resigned from her acting role as CSO per January 1, 2019. DCprime has appointed Dr Kruisbeek as Chair of the company’s Scientific Advisory Board. Dr Kruisbeek founded DCprime in 2005 and has since been ... Read more
- DCprime announces first patient dosed in phase 2 ADVANCE-II study with DCP-001 in patients with Acute Myeloid Leukemia 15 November, 2018 Leiden, The Netherlands, 15 November 2018 – DCprime bv, a clinical stage biotechnology company focused on cancer immunotherapies, announces that the first patient has been dosed with DCP-001 in a phase 2 study, called ADVANCE-II. Patients with Acute Myeloid Leukemia (AML) in complete remission after induction therapy but with persistence of measurable residual disease (MRD) ... Read more